<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561091</url>
  </required_header>
  <id_info>
    <org_study_id>AM-111-CL-13-01</org_study_id>
    <nct_id>NCT02561091</nct_id>
  </id_info>
  <brief_title>AM-111 in the Treatment of Acute Inner Ear Hearing Loss</brief_title>
  <acronym>HEALOS</acronym>
  <official_title>Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auris Medical AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auris Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the effectiveness and safety of the study drug,
      AM-111. AM-111 is tested for the treatment of sudden sensorineural hearing loss where the
      cause is unknown.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase III study is assessing the drug's safety and is aiming to demonstrate efficacy of
      intratympanic AM-111 injections in the treatment of severe to profound idiopathic sudden
      sensorineural hearing loss (ISSNHL). The active pharmaceutical ingredient of AM-111 is the
      JNK inhibitor (D-JNKI-1), a synthetic peptide consisting of 31 D-amino acids, which acts as a
      c-Jun N-terminal kinase (JNK) ligand.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pure tone average (PTA; average of the hearing threshold of three contiguous most affected hearing frequencies in dB)</measure>
    <time_frame>Day 28</time_frame>
    <description>Assessment with pure tone audiometry/ Measurement at 8 frequencies/ Final outcome is the absolute improvement in PTA from D0 to D28</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Hearing Loss</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel for intratympanic use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AM-111 0.4 mg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM-111 gel for intratympanic use (0.4 mg/ml AM-111)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AM-111 0.8 mg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM-111 gel for intratympanic use (0.8 mg/ml AM-111)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM-111 0.4 mg/ml</intervention_name>
    <arm_group_label>AM-111 0.4 mg/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM-111 0.8 mg/ml</intervention_name>
    <arm_group_label>AM-111 0.8 mg/ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Unilateral ISSNHL with onset within 72 hours prior to study treatment;

          2. Mean hearing threshold of equal to or worse than (≥) 60 dB averaged across the 3 most
             affected contiguous air conduction audiometric pure tone frequencies (&quot;pure tone
             average&quot;, PTA);*

          3. Mean hearing loss of equal to or worse than (≥) 40 dB averaged across the air
             conducted PTA frequencies compared with the unaffected contralateral ear or reference
             values from a pre-existing audiogram or ISO 7029;2000 norm values in case of
             asymmetric hearing prior to the ISSNHL incident;

          4. Age ≥ 18 and ≤ 65 years on the day of screening;

        Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          1. Bilateral ISSNHL;

          2. Acute hearing loss from noise trauma, barotrauma or head trauma;

          3. History of autoimmune hearing loss, radiation-induced hearing loss, endolymphatic
             hydrops or Menière's disease in the affected ear;

          4. History of chronic inflammatory or suppurative ear disease or cholesteatoma in the
             affected ear;

          5. History of acoustic neuroma or other retrocochlear damage in the affected ear;

          6. History of otosclerosis in the affected ear;

          7. Suspected perilymph fistula or membrane rupture in the affected ear;

          8. Congenital hearing loss;

          9. History of ISSNHL in the past 2 years;

         10. Otitis media or otitis externa that is ongoing or ended within 7 days prior to study
             treatment;

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Please check link to study webpage below for more study sites</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <link>
    <url>http://hearingloss-study.info/</url>
    <description>Study webpage with information about study and participating sites</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deafness</keyword>
  <keyword>Hearing Loss, Sensorineural</keyword>
  <keyword>Ear Diseases</keyword>
  <keyword>Hearing Disorders</keyword>
  <keyword>Otorhinolaryngologic Diseases</keyword>
  <keyword>Sensation Disorders</keyword>
  <keyword>Signs and Symptoms</keyword>
  <keyword>Hearing and Speech impairment</keyword>
  <keyword>Hearing Loss, Unilateral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

